文献速递妇科

妇科癌症临床试验未完成的相关因素分析

Factors associated with non-completion of gynecological cancer clinical trials.
PubMed 文献 · Gynecol Oncol · 2026-08-07

该研究分析了2008至2021年在美国注册的1033项妇科癌症介入性试验,发现30.3%未完成。多因素分析显示干预类型、启动年份与美国地区与未完成显著相关,2018-2021年启动的试验未完成 odds 显著高于2008-2012年,患者招募不足是最常见原因。

要点

  • 妇科癌症试验中30.3%未完成,患者招募不足占28.8%。
  • 2018-2021年启动试验未完成 odds 是2008-2012年的2.30倍。
  • 药物/生物制剂试验比多干预或其他干预试验更易未完成。

核心结论

  • 约30%的妇科癌症临床试验未能完成,启动年份等时间趋势与未完成相关。
  • 需改进试验设计与可行性规划以提升妇科肿瘤试验效率。

研究设计与样本

  • 对ClinicalTrials.gov注册的宫颈癌、卵巢癌和子宫癌介入性试验进行回顾性分析。
  • 纳入2008至2021年启动且至少有一个美国站点的已完成或未完成试验,共1033项。
  • 采用多因素logistic回归估计未完成相关因素的OR和95%CI。

主要发现

  • 纳入试验中卵巢癌占68.3%,子宫癌占25.8%,宫颈癌占24.7%。
  • 总体30.3%的试验未完成。
  • 与药物/生物制剂试验相比,多干预试验未完成OR为0.62(95%CI 0.42-0.93),其他干预试验OR为0.49(95%CI 0.25-0.98)。
  • 2018-2021年启动的试验相比2008-2012年启动者未完成OR为2.30(95%CI 1.58-3.36)。
  • 不同地区未完成存在异质性,但无地区与东北部参照组有显著差异;患者招募不足是最常见未完成原因(28.8%)。

临床怎么用

  • 设计妇科癌症临床试验时应重视可行性规划,尤其关注患者招募策略。
  • 近期启动的试验未完成风险更高,需加强过程监测与资源支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical trials are essential for advancing treatment, yet inefficiencies across the trial lifecycle may hinder progress. We evaluated trial-level characteristics associated with non-completion among gynecologic cancer clinical trials. METHODS: We conducted an analysis of interventional cervical, ovarian, and uterine cancer trials registered on ClinicalTrials.gov. Trials with at least one U.S. site initiated between 2008 and 2021 and classified as completed or not completed were included (n = 1033). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors associated with non-completion. Reasons for premature trial termination were categorized into predefined groups. RESULTS: The majority of trials included ovarian cancer (68.3%), followed by uterine (25.8%), and cervical (24.7%) cancers. Overall, 30.3% of trials did not complete. In multivariable analyses, intervention type, year of initiation, and U.S. region were significantly associated with non-completion. Compared with drug/biologic trials, those evaluating multiple (OR 0.62, 95% CI 0.42-0.93) or other interventions (OR 0.49, 95% CI 0.25-0.98) had lower odds of non-completion. Trials initiated between 2018 and 2021 had substantially higher odds of non-completion compared with trials initiated 2008-2012 (OR 2.30, 95% CI 1.58-3.36). There was also heterogeneity of non-completion across region; however, no region was significantly different from the reference category of Northeast. Insufficient patient accrual was the most common reason for non-completion (28.8%). CONCLUSIONS: Thirty percent of gynecologic cancer trials fail to complete, with temporal trends playing a role. Findings highlight the need for improved trial design and feasibility planning to enhance efficiency in gynecologic oncology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lange P, Kanal SA, Vidwans Y, et al. Factors associated with non-completion of gynecological cancer clinical trials. Gynecol Oncol. 2026. PMID: 42567119. doi:10.1016/j.ygyno.2026.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。